The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK.

DNA vaccines: designing strategies against parasitic infections. Genet Vaccines Ther (2004) 1.26

Leishmania major LACK antigen is required for efficient vertebrate parasitization. J Exp Med (2003) 1.04

Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis. Infect Immun (2005) 1.01

DNA Vaccines against Protozoan Parasites: Advances and Challenges. J Biomed Biotechnol (2007) 0.95

Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. J Immunol (2007) 0.93

Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania. Eur J Immunol (2008) 0.89

High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection. PLoS One (2012) 0.85

IL-12 and GM-CSF in DNA/MVA immunizations against HIV-1 CRF12_BF Nef induced T-cell responses with an enhanced magnitude, breadth and quality. PLoS One (2012) 0.85

Enhancing poxvirus vectors vaccine immunogenicity. Hum Vaccin Immunother (2014) 0.85

Towards development of novel immunization strategies against leishmaniasis using PLGA nanoparticles loaded with kinetoplastid membrane protein-11. Int J Nanomedicine (2012) 0.83

Identifying vaccine targets for anti-leishmanial vaccine development. Expert Rev Vaccines (2014) 0.82

Immunization against Leishmania major infection using LACK- and IL-12-expressing Lactococcus lactis induces delay in footpad swelling. PLoS One (2012) 0.80

Vaccination with L. infantum chagasi nucleosomal histones confers protection against new world cutaneous leishmaniasis caused by Leishmania braziliensis. PLoS One (2012) 0.80

Novel mucosal DNA-MVA HIV vaccination in which DNA-IL-12 plus cholera toxin B subunit (CTB) cooperates to enhance cellular systemic and mucosal genital tract immunity. PLoS One (2014) 0.78

The viral transcription group determines the HLA class I cellular immune response against human respiratory syncytial virus. Mol Cell Proteomics (2015) 0.77

Cloning and Expression of Recombinant Plasmid Containing P36/LACK Gene of Leishmania infantum Iranian Strain. Iran J Parasitol (2015) 0.75

A comprehensive analysis of LACK (Leishmania homologue of receptors for activated C kinase) in the context of Visceral Leishmaniasis. Bioinformation (2013) 0.75

Designing a DNA Vaccine-based Leishmania major Polytope (Preliminary Report). Iran J Parasitol (2017) 0.75

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med (2008) 3.42

Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog (2009) 2.24

Cellular gene expression survey of vaccinia virus infection of human HeLa cells. J Virol (2003) 1.97

Endoplasmic reticulum-Golgi intermediate compartment membranes and vimentin filaments participate in vaccinia virus assembly. J Virol (2002) 1.94

Translational resistance of late alphavirus mRNA to eIF2alpha phosphorylation: a strategy to overcome the antiviral effect of protein kinase PKR. Genes Dev (2006) 1.94

Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J Virol (2007) 1.68

The interferon system and vaccinia virus evasion mechanisms. J Interferon Cytokine Res (2009) 1.67

Microarray analysis reveals characteristic changes of host cell gene expression in response to attenuated modified vaccinia virus Ankara infection of human HeLa cells. J Virol (2004) 1.65

The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther (2008) 1.57

Vaccinia virus E3 protein prevents the antiviral action of ISG15. PLoS Pathog (2008) 1.57

Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. Proc Natl Acad Sci U S A (2011) 1.55

ISG15 regulates peritoneal macrophages functionality against viral infection. PLoS Pathog (2013) 1.51

Vaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of Plasmodium. PLoS One (2012) 1.43

TRAF family proteins link PKR with NF-kappa B activation. Mol Cell Biol (2004) 1.40

Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine (2006) 1.37

Cellular and biochemical differences between two attenuated poxvirus vaccine candidates (MVA and NYVAC) and role of the C7L gene. J Virol (2006) 1.35

Host response to the attenuated poxvirus vector NYVAC: upregulation of apoptotic genes and NF-kappaB-responsive genes in infected HeLa cells. J Virol (2006) 1.26

Administration to mice of a monoclonal antibody that neutralizes the intracellular mature virus form of vaccinia virus limits virus replication efficiently under prophylactic and therapeutic conditions. J Gen Virol (2002) 1.26

EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine (2008) 1.25

MVA and NYVAC as vaccines against emergent infectious diseases and cancer. Curr Gene Ther (2011) 1.24

Human cytomegalovirus final envelopment on membranes containing both trans-Golgi network and endosomal markers. Cell Microbiol (2009) 1.23

Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. PLoS One (2010) 1.20

Recombinant poxviruses as mucosal vaccine vectors. J Gen Virol (2005) 1.19

Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine (2006) 1.18

Resistance to viral infection of super p53 mice. Oncogene (2005) 1.17

Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. J Virol (2008) 1.17

Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PLoS One (2011) 1.16

Anti-apoptotic and oncogenic properties of the dsRNA-binding protein of vaccinia virus, E3L. Oncogene (2002) 1.15

Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens. PLoS One (2010) 1.15

Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02). Vaccine (2011) 1.15

Poxvirus vector-based HIV vaccines. Curr Opin HIV AIDS (2010) 1.14

The ESCRT machinery is not required for human cytomegalovirus envelopment. Cell Microbiol (2007) 1.13

Vaccinia virus induces apoptosis of infected macrophages. J Gen Virol (2002) 1.12

Cryo-X-ray tomography of vaccinia virus membranes and inner compartments. J Struct Biol (2009) 1.11

Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J Immunol (2013) 1.10

A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses. PLoS One (2011) 1.10

Leishmania infection: laboratory diagnosing in the absence of a "gold standard". Am J Trop Med Hyg (2010) 1.10

Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine (2003) 1.08

A poxvirus Bcl-2-like gene family involved in regulation of host immune response: sequence similarity and evolutionary history. Virol J (2010) 1.07

A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum P36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. Vaccine (2002) 1.06

Glucose induces autophagy under starvation conditions by a p38 MAPK-dependent pathway. Biochem J (2013) 1.06

Membrane cell fusion activity of the vaccinia virus A17-A27 protein complex. Cell Microbiol (2007) 1.06

The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens. J Virol (2011) 1.06

Improved NYVAC-based vaccine vectors. PLoS One (2011) 1.04

IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system. J Gen Virol (2003) 1.04

The impact of PKR activation: from neurodegeneration to cancer. FASEB J (2014) 1.04

Virus distribution of the attenuated MVA and NYVAC poxvirus strains in mice. J Gen Virol (2007) 1.02

Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. J Immunol (2004) 1.02

Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes. J Virol (2003) 1.02

Antiviral action of the tumor suppressor ARF. EMBO J (2006) 1.02

Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis. Infect Immun (2005) 1.01

Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein. PLoS One (2012) 1.01

Evidence that avian reovirus sigmaA protein is an inhibitor of the double-stranded RNA-dependent protein kinase. J Gen Virol (2003) 1.01

Preclinical evaluation of the immunogenicity of C-type HIV-1-based DNA and NYVAC vaccines in the Balb/C mouse model. Viral Immunol (2009) 1.01

Induction of protective immunity against malaria by priming-boosting immunization with recombinant cold-adapted influenza and modified vaccinia Ankara viruses expressing a CD8+-T-cell epitope derived from the circumsporozoite protein of Plasmodium yoelii. J Virol (2003) 1.01

Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother (2012) 1.00

Therapeutics and vaccines against chikungunya virus. Vector Borne Zoonotic Dis (2015) 1.00

Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells. J Virol (2003) 1.00

F11-mediated inhibition of RhoA signalling enhances the spread of vaccinia virus in vitro and in vivo in an intranasal mouse model of infection. PLoS One (2009) 0.99

Human gene profiling in response to the active protein kinase, interferon-induced serine/threonine protein kinase (PKR), in infected cells. Involvement of the transcription factor ATF-3 IN PKR-induced apoptosis. J Biol Chem (2006) 0.98

Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic. Proc Natl Acad Sci U S A (2008) 0.98

Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. J Virol (2012) 0.98

Cryo X-ray nano-tomography of vaccinia virus infected cells. J Struct Biol (2011) 0.98

DNA/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mucosa. J Virol (2011) 0.97

A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. J Virol (2014) 0.97

Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens. Vaccine (2009) 0.96

Deletion of the viral anti-apoptotic gene F1L in the HIV/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens. PLoS One (2012) 0.96

A long term experimental study of canine visceral leishmaniasis. Int J Parasitol (2006) 0.95

Clinical applications of attenuated MVA poxvirus strain. Expert Rev Vaccines (2013) 0.95

Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C. PLoS One (2013) 0.92

Improving Adaptive and Memory Immune Responses of an HIV/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways. PLoS One (2013) 0.92

Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals. PLoS One (2011) 0.92

Robust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeys. J Immunol (2010) 0.92

Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses. Vaccine (2004) 0.92

Involvement of PKR and RNase L in translational control and induction of apoptosis after Hepatitis C polyprotein expression from a vaccinia virus recombinant. Virol J (2005) 0.91

Selective induction of host genes by MVA-B, a candidate vaccine against HIV/AIDS. J Virol (2010) 0.91

A human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virus. PLoS One (2011) 0.91

Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania. Eur J Immunol (2008) 0.89

Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression. Vaccine (2010) 0.89

Targeting to porcine sialoadhesin receptor improves antigen presentation to T cells. Vet Res (2008) 0.88

Interplay between modified vaccinia virus Ankara and dendritic cells: phenotypic and functional maturation of bystander dendritic cells. J Virol (2011) 0.88

Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV/AIDS of clade C. PLoS One (2012) 0.87

Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma. Virus Res (2005) 0.86

MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis. Microbes Infect (2006) 0.86

A vaccinia virus lacking A10L: viral core proteins accumulate on structures derived from the endoplasmic reticulum. Cell Microbiol (2006) 0.86

Enhancing poxvirus vectors vaccine immunogenicity. Hum Vaccin Immunother (2014) 0.85

High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection. PLoS One (2012) 0.85

Caspase 9 activation by the dsRNA-dependent protein kinase, PKR: molecular mechanism and relevance. FEBS Lett (2002) 0.85

Regulation of vaccinia virus E3 protein by small ubiquitin-like modifier proteins. J Virol (2011) 0.85

Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge. Vaccine (2007) 0.84

The chemotherapeutic drug 5-fluorouracil promotes PKR-mediated apoptosis in a p53-independent manner in colon and breast cancer cells. PLoS One (2011) 0.84

Activation of NF-kB pathway by virus infection requires Rb expression. PLoS One (2009) 0.84

Control of virus infection by tumour suppressors. Carcinogenesis (2007) 0.84

Expression of the E3L gene of vaccinia virus in transgenic mice decreases host resistance to vaccinia virus and Leishmania major infections. J Virol (2007) 0.83

Wiskott-Aldrich syndrome protein is needed for vaccinia virus pathogenesis. J Virol (2005) 0.83

Membrane remodelling during vaccinia virus morphogenesis. Biol Cell (2009) 0.83

Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens. J Virol (2014) 0.83